Dr. Iyengar on Trastuzumab Deruxtecan in HER2-Low Breast Cancer

Now Viewing

EP: 1.Dr. Iyengar on Trastuzumab Deruxtecan in HER2-Low Breast Cancer

EP: 2.Dr. Abdou on the Significance of the DESTINY-Breast03 Trial in HER2-Positive Breast Cancer

EP: 3.Current and Emerging Trends in Breast Cancer: HER2+ and HER2-Low

Neil M. Iyengar, MD, medical oncologist, Breast Cancer, Memorial Sloan Kettering Cancer Center, discusses the use of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-low breast cancer.

HER2-low breast cancer is a newer phenotype within this disease space and other cancers, Iyengar says. Trastuzumab deruxtecan has generated activity in early-phase studies involving patients with HER2-low expressing cancers, Iyengar says. Notably, patients with triple-negative breast cancer or estrogen receptor- (ER) positive, HER2-negative breast cancer that has progressed or become endocrine insensitive are typically treated with chemotherapy, Iyengar explains.

Trastuzumab deruxtecan could represent a new therapeutic approach for patients categorized into a subgroup of low expression of HER2, Iyengar says. Future data could lead to the registration of drugs like trastuzumab deruxtecan in this space, Iyengar concludes.